natgillin/translations-raw huggingface dataset:
There may be a dose related hypertrophy of the adrenal zona glomerulosa at high dose rates.
Lahko se pojavi od odmerka odvisna hipertrofija nadledvične zone glomeruloze pri visokih odmerkih.
There may be a higher than usual chance of you getting side effects if you are also being treated with cyclosporin A. You will be monitored closely while you are taking these two medicines.
Verjetnost neželenih učinkov je lahko večja kot ponavadi, če dobivate tudi zdravilo ciklosporin A. Med uporabo teh dveh zdravil vas bodo natančno nadzirali.
There may be a little bleeding at the injection site.
Na mestu injiciranja se lahko pojavi rahla krvavitev.
There may be a local reaction at the injection site, such as swelling (lasting no more than one week) or ‘nodules’ (hardening under the skin) possibly lasting more than six or seven weeks.
Po cepljenju se lahko pojavi lokalna reakcija na mestu injiciranja, kot je oteklina (ki ne traja več kot teden dni) ali „noduli“ (zatrdline pod kožo), ki lahko trajajo več kot šest ali sedem tednov.
There may be a local reaction at the injection site, with slight pain on touching, itching or oedema (swelling), which disappears within one or two weeks.
Na mestu injiciranja se lahko pojavi lokalna reakcija z rahlo bolečino ob dotiku, srbečico ali edemom (oteklino), ki izgine v enem tednu ali dveh.
There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co- administered with HCT or any combination with HCT.
Ob sočasni uporabi memantina in hidroklorotiazida (HCT) oziroma zdravil, ki vsebujejo HCT, lahko pride do zmanjšanja serumske koncentracije HCT.
There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.
Ob sočasni uporabi memantina in hidroklorotiazida (HCT) oziroma zdravil, ki vsebujejo HCT, lahko pride do zmanjšane serumske koncentracije HCT.
There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.
Obstaja možnost zmanjšane serumske koncentracije hidroklorotiazida (HCT) ob sočasni uporabi memantina in HCT oziroma kakršnikoli kombinacij s HCT.
There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.
Obstaja možnost zmanjšane serumske koncentracije hidroklorotiazida (HCT) ob sočasni uporabi memantina in HCT oziroma kakršnikoli kombinaciji s HCT.
There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.
Obstaja možnost zmanjšane serumske koncentracije hidroklorotiazida (HCT) ob sočasni uporabi memantina in HCT, oziroma zdravil, ki vsebujejo HCT.
There may be a small amount of blood or liquid at the injection site.
Morda bo iz mesta injiciranja priteklo nekaj kapelj krvi ali tekočine.
There may be a small amount of blood or liquid at the injection site.
Na mestu injiciranja boste morda opazili majhno količino krvi ali tekočine.
There may be a small amount of blood or liquid at the injection site.
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
There may be additional information in those leaflets about situations when Norvir should be avoided.
Lahko namreč vsebujejo dodatne informacije o okoliščinah, v katerih ne smete jemati zdravila Norvir.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Sepioglin.
Obstaja povečana možnost zanositve, ker lahko spet pride do ovulacije, ko ste vzeli zdravilo Sepioglin .
There may be an increased risk of angioedema in patients concomitantly taking ACE-inhibitors.(see section 4.8).
Pri bolnikih, ki sočasno jemljejo zaviralce angitenzinske konvertaze, je lahko prisotno povečano tveganje za angioedem (glejte poglavje 4.8).
There may be an increased risk of developing an inflammation of the pancreas (pancreatitis) in children compared to adults treated with growth hormone.
Tveganje za pojav vnetja trebušne slinavke (pankreatitis) je med zdravljenjem z rastnim hormonom večje pri otrocih kot pri odraslih.
There may be loss of feeling in the affected area, or sensations such as touch, heat, cold or pressure may cause pain)
V prizadetem področju lahko pride do izgube zaznavanja, ali pa lahko občutki, denimo dotik, toplota, mraz ali pritisk, povzročajo bolečino)
There may be some irritation, a burning sensation or skin damage where Foscan is injected, but this will not last long.
Pojavijo se lahko tudi draženje, pekoč občutek ali poškodbe kože na mestu injiciranja zdravila Foscan, a to ne bo trajalo dolgo.
There may be some small air bubbles that stick to the inner wall of the reservoir holder left in the pen.
Morda boste v injekcijskem peresniku videli majhne zračne mehurčke, ki se držijo notranje stene prostora za tekočino.
There may be swelling or you may have a stiff jaw.
Možne so otekline ali težje gibljiva čeljust.
There may still be some medicine in the vial.
V viali lahko ostane nekaj zdravila.
There must be at least 48 hours in between each time you take SIRTURO.
Med dvema odmerjanjema zdravila SIRTURO mora preteči najmanj 48 ur.
There must be at least a 4- week waiting period between end of treatment with sorivudine or its chemically related analogues such as brivudine and start of capecitabine therapy.
Med zaključkom zdravljenja s sorivudinom ali kemično podobnimi analogi, kot je brivudin, in začetkom zdravljenja s kapecitabinom mora biti vsaj 4-tedenski premor.
There should be 2–3 days without Protopic treatment between applications.
Med eno in drugo uporabo zdravila Protopic morajo miniti 2–3 dnevi brez zdravljenja.
There should be 3 types of treatment initiation forms:
Obstajajo naj 3 vrste obrazcev za začetek zdravljenja:
There should be a 12 hour gap between doses.
Med odmerki naj bo 12-urni presledek.
There should be a hole at the top of the tube.
Na vrhu tube mora biti luknjica.
There should be an interval of at least 1 month between primary doses.
Med posameznimi odmerki v primarnem cepljenju mora miniti vsaj 1 mesec.
There should be an interval of at least 2 months between primary doses.
Med primarnima odmerkoma morata miniti vsaj 2 meseca.
There was a 1.6% reduction in the patients who added placebo to their existing treatment.
Pri bolnikih, ki so kot pomožno zdravilo prejemali placebo, so opazili zmanjšanje števila napadov za 1,6 %.
There was a 2.5- to 3-fold increase in steady-state AUC as the dose was increased from 500 mg to 1000 mg twice daily.
V dinamičnem ravnovesju je bilo povečanje AUC 2,5–3-kratno, ko se je odmerek povečal s 500 mg na 1000 mg dvakrat na dan.
There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3 % versus 0.4 %, respectively).
Pri bolnikih, zdravljenih z olanzapinom, je bila 3-krat večja pojavnost CVAE v primerjavi z bolniki, ki so prejemali placebo (1,3-% v primerjavi z 0,4-%).
There was a clear immune response to Nobilis IB 4-91.
Zdravilo Nobilis IB 4-91 je izzvalo dober imunski odziv.
There was a dose- dependent increase in foetal losses and increased neonatal mortality beginning in the third trimester.
Poročali so o od odmerka odvisnem povečanju izgub plodov in o večji neonatalni umrljivosti od tretjega trimesečja dalje.
There was a higher incidence of discontinuations in patients taking the 25 mg dose compared to placebo due to diarrhoea (0.7% for placebo versus 3.1% for naloxegol 25 mg) and abdominal pain (0.2% versus 2.9%, respectively).
Incidenca prekinitev je bila pri bolnikih, ki so dobivali odmerek 25 mg, večja kot med prejemniki placeba, in sicer tako zaradi driske (0,7 % za placebo in 3,1 % za 25 mg naloksegola) kot zaradi bolečin v trebuhu (0,2 % za placebo in 2,9 % za 25 mg naloksegola).
There was a higher incidence of grade 4 febrile neutropenia observed (1.7% in MPR+R/MPR+p compared to 0.0% in MPp+p).
Opazili so večjo incidenco febrilne nevtropenije stopnje (1,7 % pri MPR+R/MPR+p v primerjavi z 0,0 % pri MPp+p).
There was a higher incidence of Grade ≥3 adverse reactions, adverse reactions leading to discontinuation and a higher rate of haematological toxicity in the elderly population compared to the overall study population (see section 4.2).
Pri primerjavi s splošno proučevano populacijo so bili pri starejših pogostejši neželeni učinki stopnja ≥ 3, neželeni učinki, zaradi katerih je bilo zdravljenje ukinjeno, in hematološki toksični učinki (glejte poglavje 4.2).
There was a higher rate of central nervous system (CNS) bleeding in the drotrecogin alfa (activated) versus the placebo group.
Stopnja krvavitve v osrednje živčevje je bila višja v skupini, ki je prejemala drotrekogin alfa (aktiviranega) v primerjavi s skupino, ki je prejemala placebo.
There was a higher rate of serious adverse events, including pneumonia, acute rejection, graft loss and death, in this sirolimus treatment arm (n=60, median time post-transplant 36 months).
Delež resnih neželenih učinkov, vključno s pljučnico, akutno zavrnitvijo, izgubo presadka in smrtjo, je bil namreč v tej podskupini, zdravljeni s sirolimusom, večji (n=60, srednji čas po presaditvi 36 mesecev).
There was a low frequency (approximately 3%) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim.
V kliničnem preskušanju bolnikov s hudo kronično nevtropenijo, ki so dobivali filgrastim, so poročali o mielodisplastičnih sindromih (MDS) ali levkemiji, ki pa niso bili pogosti (pri približno 3
There was a low frequency (approximately 3%) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim.
V kliničnem preskušanju bolnikov s hudo kronično nevtropenijo, ki so dobivali filgrastim, so poročali o mielodisplastičnih sindromih (MDS) ali levkemiji, ki pa niso bili pogosti (pri približno 3%).
There was a low, similar overall incidence of virologic failure (viral load > 50 copies/ml) in both the once and twice daily treatment groups (10% and 8% respectively).
Pri obeh režimih zdravljenja je bil virusni neodziv (obremenitev z virusom > 50 kopij/ml) nizek: v skupini z režimom odmerjanja enkrat dnevno 10 % in v skupini z režimom odmerjanja dvakrat dnevno 8 %.
There was a marked depression of urinary markers of bone resorption (pyridinoline and deoxypyridinoline) in patients treated with Bondronat that was statistically significant compared to placebo.
V primerjavi s placebom se je pri bolnikih zdravljenih z zdravilom Bondronat v urinu pojavilo statistično značilno izrazito zmanjšanje označevalcev kostne resorpcije (piridinolina in deoksipiridinolina).
There was a mean increase of 22.2  109/l in platelet count, and a mean increase of 0.95 g/dl in haemoglobin concentration.
Povprečno povečanje koncentracije trombocitov je bilo 22,2  109/l, povprečno povišanje koncentracije hemoglobina pa 0,95 g/dl.
There was a numerical imbalance in non-CV death, with more events on saxagliptin (1.8%) than placebo (1.4%) [HR=1.27; (95% CI 1.00, 1.62); P=0.051].
Obstajalo je številsko neravnovesje smrti zaradi drugih vzrokov, kot so srčno-žilni, in sicer z več dogodki v skupini s saksagliptinom (1,8 %) kot v skupini s placebom (1,4 %) [razmerje ogroženosti 1,27, (95 % IZ: 1,00, 1,62), p = 0,051].
There was a reduction of about 20 to 30% in ‘off’ time in patients taking Tasmar.
Pri bolnikih, ki so jemali zdravilo Tasmar, se je prekinitveno obdobje skrajšalo za 20 do 30 %.
There was a significant higher rate of tumour response of 14.4% (95%CI: 9.6-19.3) in patients in the JEVTANA arm compared to 4.4% (95%CI: 1.6-7.2) for patients in the mitoxantrone arm, p=0.0005.
V kraku z zdravilom JEVTANA je bil delež odziva tumorja značilno večji (14,4 %, 95 % IZ: 9,6–19,3) kot v kraku z mitoksantronom (4,4 %, 95 % IZ: 1,6–7,2), p = 0,0005.
There was a significant improvement of DAS in Studies II, III, V, and VI as compared to placebo or comparator.
V študijah II, III, V in VI so opazili pomembno izboljšanje DAS v primerjavi s placebom ali primerjalnim zdravilom.
There was a significant increase in heart failure (fatal and non- fatal) (HR 2.10, CI 1.35-3.27) and bone fractures (Risk Ratio 1.57, CI 1.26-1.97) in rosiglitazone- containing treatments compared to active control (see sections 4.4 and 4.8).
Med zdravljenji, ki so vključevala rosiglitazon, so v primerjavi s primerjalno učinkovino ugotovili značilno več srčnega popuščanja (s smrtnim izidom ali brez njega) (razmerje ogroženosti 2,10, IZ 1,35-3,27) in zlomov kosti (razmerje tveganj 1,57, IZ 1,26-1,97) (glejte poglavji 4.4 in 4.8).
There was a significant risk reduction in favour of the edoxaban 60 mg treatment group compared with the warfarin group in major bleeding (2.75%, and 3.43% per year, respectively) [HR (95% CI): 0.80 (0.71, 0.91); p = 0.0009], ICH (0.39%, and 0.85% per year, respectively) [HR (95% CI): 0.47 (0.34,
Tveganje je bilo signifikantno zmanjšano v korist skupini, zdravljeni z edoksabanom 60 mg, v primerjavi s skupino z varfarinom pri veliki krvavitvi (2,75 % oziroma 3,43 % na leto) [HR (95 % CI): 0,80 (0,71, 0,91); p = 0,0009], intrakranialni krvavitvi (ICH) (0,39 % oziroma 0,85 % na leto) [HR
There was a significant therapeutic benefit from the use of enoxaparin in comparison to UFH in patients undergoing percutaneous coronary angioplasty within 30 days after the random sampling (relative risk reduction of 23%) or conservative treatment (reduction of relative risk of 15%, p = 0.27 for interaction).
Enoksaparin je v primerjavi z nefrakcioniranim heparinom pokazal značilno terapevtsko korist pri bolnikih, pri katerih so v 30 dneh po randomizaciji opravili perkutano koronarno angioplastiko (23- odstotno zmanjšanje relativnega tveganja) oziroma so prejeli konservativno zdravljenje (15-odstotno zmanjšanje relativnega tveganja, p =0,27 za interakcijo).
There was a significant therapeutic benefit from the use of enoxaparin in comparison to UFH in patients undergoing percutaneous coronary angioplasty within 30 days after the random sampling (relative risk reduction of 23%) or conservative treatment (reduction of relative risk of 15%, p = 0.27 for interaction).
Enoksaparin je v primerjavi z nefrakcioniranim heparinom pokazal značilno terapevtsko korist pri bolnikih, pri katerih so v 30 dneh po randomizaciji opravili perkutano koronarno angioplastiko (23- odstotno zmanjšanje relativnega tveganja) oziroma so prejeli konzervativno zdravljenje (15-odstotno zmanjšanje relativnega tveganja, p =0,27 za interakcijo).
There was a significantly (p<0.05) greater incidence of cardiovascular/thromboembolic events (myocardial infarction, ischemia, cerebrovascular accident, deep vein thrombosis and pulmonary embolism) detected in the parecoxib/valdecoxib treatment group compared to the placebo/placebo treatment group for the IV dosing period (2.2% and 0.0% respectively) and over the entire study period (4.8% and 1.3% respectively).
Znatno večjo pojavnost (p < 0,05) kardiovaskularnih/trombemboličnih dogodkov (miokardni infarkt, ishemijo, cerebrovaskularni insult, globoko vensko trombozo in pljučno embolijo) so odkrili pri skupini, zdravljeni s parekoksibom/valdekoksibom, v primerjavi s skupino, ki je v obdobju i.v. odmerjanja prejemala placebo/placebo (2,2 % oz.
There was a slightly higher incidence of overall haematological and myelosuppression-related adverse reactions for patients who received prior radiotherapy compared to patients without prior radiotherapy in RECOURSE (54.6% versus 49.2%, respectively), of note febrile neutropenia was higher in
Pri bolnikih v preskušanju RECOURSE, ki so predhodno prejemali obsevalno zdravljenje, je bila pojavnost celokupnih hematoloških neželenih učinkov in neželenih učinkov, povezanih s supresijo kostnega mozga, rahlo večja kot pri bolnikih, ki niso bili obsevani (54,6 % v primerjavi z 49,2 %).
There was a small increase in plasma concentrations of capecitabine and one metabolite (5’-DFCR); there was no effect on the 3 major metabolites (5’-DFUR, 5-FU and FBAL).
V plazmi so opazili majhno povečanje koncentracij kapecitabina in enega presnovka (5'-DFCR); na preostale tri glavne presnovke (5'-DFUR, 5-FU in FBAL) pa ni vplival.
There was a small increase in plasma concentrations of capecitabine and one metabolite (5’-DFCR); there was no effect on the 3 major metabolites (5’-DFUR, 5-FU and FBAL).
V plazmi so opazili majhno povečanje koncentracij kapecitabina in enega presnovka (5´-DFCR); na preostale tri glavne presnovke (5´-DFUR, 5-FU in FBAL) pa ni vplival.
There was a statistically significant (p=0.0017) difference in the changes in mean values from baseline between treatment groups at 12 hours, demonstrating the association of Cinryze treatment with an increase in C4 activity (Cinryze + 2.9 mg/dl versus placebo + 0.1 mg/dl).
Razlika med spremembami povprečnih vrednosti od izhodišča med zdravljenima skupinama po 12 urah je bila statistično značilna (p=0,0017), kar dokazuje povezavo med zdravljenjem z zdravilom Cinryze in zvišanjem aktivnosti C4 (Cinryze + 2,9 mg/dl proti placebu + 0,1 mg/dl).
There was a statistically significant increase in mammary gland adenocarcinomas in female rats at 10, 30 and 60 mg/kg/month.
Pri odmerkih 10, 30 in 60 mg/kg/mesec je bila pojavnost adenokarcinomov mlečnih žlez pri samicah podgan statistično značilno zvečana.
There was a statistically significant sustained platelet or hemoglobin improvement in the ITT population in favor of ibrutinib versus chlorambucil.
Pri ITT populaciji bolnikov je v prid ibrutinibu v primerjavi s klorambicilom prišlo do statistično značilnega dolgotrajnega izboljšanja v številu trombocitov ali koncentraciji hemoglobina.
There was a statistically significant treatment difference in favour of Abilify Maintena 400 mg/300 mg compared to placebo at week 10 (+7.1, p < 0.0001, 95 % CI: 4.1, 10.1 using an ANCOVA model (LOCF)).
Opazili so statistično pomembno razliko v zdravljenju z zdravilom Abilify Maintena 400 mg/300 mg v primerjavi s placebom v 10. tednu (+7,1, p < 0,0001, 95-odstotni IZ: 4,1, 10,1 z modelom ANCOVA (LOCF)).
There was a sustained effect over time in the six- months and one-year Phase III studies.
V šestmesečnih in enoletnih študijah 3. faze se ta učinek s časom ni zmanjševal.
There was a transient increase in serum creatinine observed within 10 days in 1.8% of Aclasta-treated patients versus 0.8% of placebo-treated patients.
V prvih 10 dneh po odmerjanju je prišlo do prehodnega zvišanja vrednosti kreatinina v serumu pri 1,8 % bolnikov v skupini z zdravilom Aclasta v primerjavi z 0,8 % bolnikov v skupini s placebom.
There was a trend for better results in patients with reduced kidney function than those whose kidney function was normal.
Izkazalo se je, da so bili rezultati boljši pri bolnikih z zmanjšanim delovanjem ledvic kot pri bolnikih z normalnim delovanjem ledvic.
There was also a subpopulation of 16 advanced phase patients (5 AP CML and 11 BP CML patients) that failed treatment with either imatinib alone or imatinib in addition to one or both second- generation TKIs (dasatinib and nilotinib) and for whom, based on the presence of co-morbidities, a history of TKI intolerance, or a BCR-ABL resistance mutation, the remaining approved TKI(s) were not considered appropriate treatment options.
V študiji je obstajala podpopulacija 16 bolnikov v napredovali fazi (5 bolnikov s KML v pospešeni fazi, 11 bolnikov s KML v blastni fazi), pri katerih zdravljenje z imatinibom samim ali imatinibom ter enim ali obema TKI druge generacije (dasatinib in nilotinib) ni bilo uspešno in za katere (glede na sočasno prisotne bolezni, anamnezo neprenašanja TKI ali mutacijo BCR-ABL, ki je povzročila neodzivnost) preostali odobreni TKI niso primerna terapevtska možnost.
There was also an increased incidence of pneumonias resulting in hospitalisation.
Večja je bila tudi incidenca pljučnic, ki so zahtevale sprejem v bolnišnico.
There was also no clinically significant food effect observed between administration of FDC in the fasted or fed state.
Pri dajanju kombinacije abakavir/lamivudin v fiksnem odmerku na tešče ali po hranjenju je bilo ravno tako ugotovljeno, da hrana nima klinično pomembnega vpliva.
There was also supportive evidence suggesting benefit when the medicine was combined with insulin.
Na voljo so bili tudi podporni dokazi, ki nakazujejo na koristi zdravila pri sočasni uporabi z insulinom.
There was an apparent dose-relationship for dizziness, somnolence, confusional state, aphasia, coordination abnormal, tremor, balance disorder, memory impairment, gait disturbance, blurred vision and constipation.
Očitno z odmerkom povezano razmerje so ugotovili za omotico, somnolentnost, stanje zmedenosti, afazijo, nenormalno koordinacijo, tremor, motnje ravnotežja, okvaro spomina, motnje hoje, zamegljen vid in zaprtost.
There was an approximately 8%, 23% and 34% increase in the inhibition of LMP7, MECL1, and LMP2 subunits respectively at the dose of 56 mg/m2compared to those at 15 to 20 mg/m2.
Z odmerkom 56 mg/m2 se je v primerjavi z odmerki od 15 do 20 mg/m2 zavrtje LMP7 povečalo za približno 8 %, zavrtje MECL1 za približno 23 % in zavrtje LMP2 za približno 34 %.
There was an average decrease in susceptibility of 2-fold wild type (WT) for tipranavir, 12-fold WT for amprenavir, 55-fold WT for atazanavir, 41-fold WT for indinavir, 87-fold WT for lopinavir, 41- fold WT for nelfinavir, 195-fold WT for ritonavir, and 20-fold WT for saquinavir.
Povprečno zmanjšanje občutljivosti je bilo 2-kratno glede na divji tip za tipranavir, 12-kratno glede na divji tip za amprenavir, 55-kratno glede na divji tip za atazanavir, 41-kratno glede na divji tip za indinavir, 87-kratno glede na divji tip za lopinavir, 41-kratno glede na divji tip za nelfinavir, 195-kratno glede na divji tip za ritonavir in 20-kratno glede na divji tip za sakinavir.
There was an average decrease of 36-39% in systemic exposure in healthy subjects when co-administered with eslicarbazepine acetate 1,200 mg once daily.
Pri sočasni uporabi z eslikarbazepinacetatom v odmerku 1.200 mg enkrat dnevno je prišlo do povpre čnega znižanja sistemske izpostavljenosti za 36 - 39% pri zdravih preskušancih.
There was an average decrease of 36-39% in systemic exposure in healthy subjects when co-administered with eslicarbazepine acetate 1,200 mg once daily.
Pri sočasni uporabi z eslikarbazepinacetatom v odmerku 1.200 mg enkrat dnevno je prišlo do povprečnega znižanja sistemske izpostavljenosti za 36 - 39% pri zdravih preskušancih.
There was an improvement in cardiac T2* of more than 3 milliseconds in patients treated with Ferriprox compared with a change of about 1 millisecond in patients treated with deferoxamine.
Prišlo je do izboljšanja v srčnem T2* za več kot 3 milisekunde pri pacientih, ki so jih zdravili z zdravilom Ferriprox v primerjavi s spremembo približno 1 milisekunde pri pacientih, ki so jih zdravili z deferoksaminom.
There was an increase
podaljšanju najdaljšega
There was an increase in clearance (CL) at Week 14 that resolved with continued rFVIIIFc treatment.
Očistek se je v 14. tednu povečal, z nadaljevanjem zdravljenja z rFVIIIFc pa je povečanje izzvenelo.
There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of A771726, suggesting that A771726 is an inhibitorof OAT 3 in vivo.
Po večkratnih odmerkih A771726 so ugotovili povečanje povprečne Cmax cefaklorja za 1,43-krat in njegove povprečne AUC za 1,54-krat; to kaže, da A771726 in vivo zavira OAT3.
There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of OAT3 in vivo.
Po ponavljajočih se odmerkih teriflunomida so ugotovili povečanje povprečnih vrednosti Cmax (1,43-krat) in AUC (1,54-krat) cefaklora, kar nakazuje, da je teriflunomid zaviralec OAT3 in vivo.
There was an increase in mean ethinylestradiol Cmax and AUC0-24 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC0-24 (1.33- and 1.41-fold, respectively) following repeated doses of A771726.
Po ponavljajočih se odmerkih A771726 se je povprečna Cmax etinilestradiola povečala za 1,58-krat in njegova povprečna AUC0-24 za 1,54-krat; povprečna Cmax levonorgestrela se je povečala za 1,33-krat in povprečna AUC0-24 za 1,41-krat.